q is an integer of 0 or 1;

R^1 is hydrogen, alkyl, or halo;

R^2 is alkyl or halo;

R^3 is halo;

R^9 is hydrogen, alkyl, or heterocycloalkyl;

wherein alkyl is optionally substituted with one or more halo.

[0009b] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising the compound as disclosed herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0009c] In a further aspect of the present disclosure, there is provided a use of a compound as disclosed herein or a pharmaceutical composition as disclosed herein, in the manufacture of a medicament for the treatment of a disorder in a subject, wherein said disorder is one or more of cancer, bone disorder, inflammatory disease, immune disease, respiratory disease, thrombosis, or cardiac disease.


[0009d] In another aspect of the present disclosure, there is provided a use of a compound as disclosed herein or a pharmaceutical composition as disclosed herein, in the manufacture of a medicament for the treatment of one or more of asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder (COPD), psoriasis, multiple sclerosis, disorders related to diabetic complications, lupus erythematosus, scleroderma, graft versus host disease, restenosis, or atherosclerosis in a subject.

[0009e] In a further aspect of the present disclosure, there is provided a use of a compound as disclosed herein or a pharmaceutical composition as disclosed herein, in the manufacture of medicament for the treatment of cancer in a subject.

[0009f] In another aspect of the present disclosure, there is provided a use of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder in a subject, wherein the disorder is selected from one or more of cancer, bone disorder, inflammatory disease, immune disease, respiratory disease, thrombosis, and cardiac disease.


[0009g] In a further aspect of the present disclosure, there is provided a use of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject.

[0009h] In a further aspect of the present disclosure, there is provided a compound of the formula:



(Compound 292).


[0009i] In another aspect of the present disclosure, there is provided a process for preparing a compound of formula:



or a pharmaceutically acceptable salt thereof, wherein

R^3 is halo;


comprising deprotecting a compound of formula:



wherein the deprotection occurs in the presence of an acid.

[0009j] In a further aspect of the present disclosure, there is provided a compound disclosed herein or a pharmaceutical composition disclosed herein, for use in the treatment of a disorder in a subject, wherein said disorder is one or more of cancer, bone disorder, inflammatory disease, immune disease, respiratory disease, thrombosis, or cardiac disease; or for use in the treatment of asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder (COPD), psoriasis, multiple sclerosis, disorders related to diabetic complications, lupus erythematosus, scleroderma, graft versus host disease, restenosis, or atherosclerosis.

[0010] The present disclosure also provides compounds of Formula I below or pharmaceutically acceptable salts thereof, wherein



Formula I


[0011] W_d is heterocycloalkyl, aryl or heteroaryl;

[0012] B is alkyl or a moiety of Formula II;

CLAIMS

WHAT IS CLAIMED IS:


1. A compound of Formula V-A:



Formula V-A

or a pharmaceutically acceptable salt thereof, wherein

B is a moiety of Formula II:



;

Formula II

wherein W_c is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl;

q is an integer of 0 or 1;

R^1 is hydrogen, alkyl, or halo;


R^2 is alkyl or halo;

R^3 is halo;

R^9 is hydrogen, alkyl, or heterocycloalkyl;

wherein alkyl is optionally substituted with one or more halo.

2. The compound of claim 1 of the Formula V-A2:



Formula V-A2

or a pharmaceutically acceptable salt thereof.


3. The compound of claim 1 or 2, wherein R^3 is -F.

4. The compound of claim 1 or 2, wherein R^3 is -Cl.


5. The compound of any one of claims 1-4, wherein R^9 is $-CH_3$ or $-CH_2CH_3$.

6. The compound of any one of claims 1-5, wherein W_c is phenyl or cyclopropyl, which is optionally substituted with at least one of $-CH_3$, $-CH_2CH_3$, $-CF_3$, -Cl, or -F.


7. The compound of any one of claims 1-6, wherein the compound is a compound of formula:




,




,



,




, or




,

or a pharmaceutically acceptable salt thereof.


8. The compound of claim 1, wherein the compound is selected from:




Compound 363,




Compound 364,




Compound 365




Compound 366,




Compound 332,




Compound 331




Compound 330,




Compound 329,



Compound 328,






,

Compound 270, and Compound 292,

or a pharmaceutically acceptable salt thereof.


9. The compound of claim 1, wherein the compound is:



(Compound 237),

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, wherein the compound is:



(Compound 292),

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 or 9, wherein the compound is the S-enantiomer having an enantiomeric purity greater than 55%, greater than 80%, greater than 90%, or greater than 95%.

12. A pharmaceutical composition comprising the compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

13. A pharmaceutical composition comprising the compound of claim 10, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

14. Use of a compound of any one of claims 1-11 or a pharmaceutical composition of claim 12 or 13 in the manufacture of a medicament for the treatment of a disorder in a subject, wherein said disorder is one or more of cancer, bone disorder, inflammatory disease, immune disease, respiratory disease, thrombosis, or cardiac disease.

15. Use of a compound of any one of claims 1-11 or a pharmaceutical composition of claim 12 or 13 in the manufacture of a medicament for the treatment of one or more of asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder (COPD), psoriasis, multiple sclerosis, disorders related to diabetic complications, lupus erythematosus, scleroderma, graft versus host disease, restenosis, or atherosclerosis in a subject.

16. Use of a compound of any one of claims 1-11 or a pharmaceutical composition of claim 12 or 13 in the manufacture of a medicament for the treatment of cancer in a subject.

17. The use of claim 16, wherein the cancer is a leukemia or a lymphoma.

18. The use of claim 16, wherein the cancer is selected from thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian,

prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS-related cancer, Kaposi's Sarcoma, mastocytosis, and viral-induced cancer.

19. The use of claim 16, wherein the cancer is selected from acute myelogenous leukemia (AML), acute lymphocytic leukemia, T-cell acute lymphocytic leukemia, chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia (CML), multiple myeloma (MM), myelodysplastic syndrome (MDS), human lymphotropic virus-type 1 (HTLV-1) leukemia, and B-cell acute lymphoblastic leukemia.

20. The use of claim 16, wherein the cancer is selected from diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, adult T-cell lymphoma, mantle cell lymphoma (MCL), Hodgkin disease, non-Hodgkin lymphomas, AIDS-related lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, multiple myeloma, and follicular lymphoma.

21. The use of claim 14, wherein the inflammatory or immune disease is one or more of:

(i) bursitis, lupus, acute disseminated encephalomyelitis (ADEM), Addison‘s disease, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, coeliac disease, Crohn‘s disease, diabetes mellitus (type 1), Goodpasture's syndrome, Graves‘ disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, inflammatory bowel disease, lupus erythematosus, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord‘s thyroiditis, ostheoarthritis, uveoretinitis, pemphigus, polyarthritis, primary biliary cirrhosis, Reiter‘s syndrome, Takayasu‘s arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, alopecia universalis, Chagas‘ disease, chronic fatigue syndrome, dysautonomia, endometriosis, hidradenitis suppurativa, interstitial cystitis, neuromyotonia, sarcoidosis, scleroderma, ulcerative colitis, vitiligo, vulvodynia, appendicitis, arteritis, arthritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis,

gingivitis, hepatitis, hidradenitis, ileitis, iritis, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, and vulvitis;

(ii) perennial allergic rhinitis, mesenteritis, acrodermatitis, angiodermatitis, atopic dermatitis, contact dermatitis, eczema, erythema multiforme, intertrigo, Stevens Johnson syndrome, toxic epidermal necrolysis, skin allergy, severe allergic reaction/anaphylaxis, allergic granulomatosis, allergic conjunctivitis, chorioretinitis, infectious keratoconjunctivitis, keratoconjunctivitis, ophthalmia neonatorum, trachoma, ocular inflammation, blepharoconjunctivitis, pericoronitis, rhinopharyngitis, sialadenitis, musculoskeletal system inflammation, adult onset Stills disease, Behcets disease, chondrocalcinosis, dactylitis, Felty syndrome, gout, infectious arthritis, Lyme disease, inflammatory osteoarthritis, periarthritis, Ross River virus infection, acute respiratory distress syndrome, acute bronchitis, acute sinusitis, allergic rhinitis, asthma, severe refractory asthma, pleurisy, seasonal allergic rhinitis, status asthmaticus, tracheobronchitis, serositis, neuromyelitis optica, poliovirus infection, Alport syndrome, balanitis, epididymo orchitis, focal segmental, glomerulosclerosis, glomerulonephritis, IgA nephropathy (Berger's Disease), orchitis, parametritis, pelvic inflammatory disease, pyelitis, pyelocystitis, hyperuricemia, aortitis, chylopericarditis, Dressler syndrome, endarteritis, extracranial temporal arteritis, HIV associated arteritis, intracranial temporal arteritis, Kawasaki disease, lymphangiophlebitis, Mondor disease, and periarteritis; and

(iii) jejunitis, mucositis, non alcoholic steatohepatitis, non viral hepatitis, autoimmune pancreatitis, perihepatitis, pouchitis, pseudomembranous colitis, rectosigmoiditis, salpingoperitonitis, sigmoiditis, steatohepatitis, Churg Strauss syndrome, ulcerative proctitis, irritable bowel syndrome, gastrointestinal inflammation, acute enterocolitis, anusitis, Balser necrosis, diverticulitis, enterohepatitis, eosinophilic esophagitis, esophagitis, hemorrhagic enteritis, hepatitis virus infection, hepatocholangitis, hypertrophic gastritis, ileocecitis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic

arthritis, cutaneous lupus, systemic lupus, lupus nephritis, AIDS, agammaglobulinemia, AIDS related complex, Brutons disease, Chediak Higashi syndrome, common variable immunodeficiency, DiGeorge syndrome, dysgammaglobulinemia, immunoglobulindeficiency, Job syndrome, Nezelof syndrome, phagocyte bactericidal disorder, Wiskott Aldrich syndrome, asplenia, elephantiasis, hypersplenism, lymphadenopathy, lymphedema, lymphocele, Nonne Milroy Meige syndrome, spleen disease, splenomegaly, thymoma, thymus disease, perivasculitis, pleuropericarditis, polyarteritis nodosa, thromboangiitis, thromboangiitis obliterans, thromboendocarditis, thrombophlebitis, and chronic obstructive pulmonary disease (COPD).

22. The use of claim 14, wherein the inflammatory or immune disease is asthma.

23. The use of claim 14, wherein the inflammatory or immune disease is rheumatoid arthritis.

24. The use of claim 23, wherein the compound is used in an amount effective to ameliorate one or more symptoms associated with rheumatoid arthritis selected from one or more of a reduction in the swelling of the joints, a reduction in serum anti-collagen levels, a reduction in bone resorption, a reduction in cartilage damage, a reduction in pannus, and a reduction in inflammation.

25. The use of any one of claims 14-24, further comprises use of one or more second therapeutic agents.

26. The use of claim 25, wherein the second therapeutic agent is a chemotherapeutic agent, optionally
wherein the chemotherapeutic agent is selected from mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, anti-androgens, alkyl sulfonates, aziridines, ethylenimines, methylamelamines, nitrogen mustards, nitrosureas, folic acid analogues, purine analogues, folic acid replenishers, taxanes, anti-estrogens, LHRH agonists, photodynamic therapies, triazenes, platinum containing

compounds, vinca alkaloids, taxoids, epipodophyllins, DHFR inhibitors, IMP dehydrogenase inhibitors, ribonucleotide reductase inhibitors, uracil analogues, cytocine analogues, Vitamin D analogues, isoprenylation inhibitors, dopaminergic neurotoxins, MDR inhibitors, Ca2+ ATPase inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, and mTOR inhibitors; optionally wherein the chemotherapeutic agent is selected from the group consisting of imatinib, bortezomib, bicalutamide, adriamycin, thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide, trimethylolomelamine, chlorambucil, chlornaphazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, chlorozotocin, fotemustine, nimustine, ranimustine; aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, 5-fluorouracil (5-FU), denopterin, pteropterin, trimetrexate, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfomithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguazone, mopidamol, nitracrine, pentostatin, phenamet; pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, sizofiran, spirogermanium; tenuazonic acid, triaziquone, 2,2',2"-trichlorotriethylamine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside (“Ara-C”), paclitaxel, docetaxel, retinoic acid, esperamicins, capecitabine, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, toremifene, flutamide, nilutamide, leuprolide, goserelin, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin,

carboplatin, vinblastine, platinum, mitomycin C, mitoxantrone, vincristine, vinorelbine, navelbine, novantrone, teniposide, daunomycin, aminopterin, xeloda, ibandronate, camptothecin-11 (CPT-11), topoisomerase inhibitor RFS 2000, difluoromethylornithine (DMFO), tamoxifen, raloxifene, megestrol, vertoporfin(BPD-MA), phthalocyanine, photosensitizer Pc4, demethoxy-hypocrellin A (2BA-2-DMHA), carmustine (BCNU), lomustine (CCNU), treosulfan, temozolomide, oxaliplatin, DHA-paclitaxel, Taxoprexin, PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX, ANG1005, paclitaxel-EC-1, glucose-conjugated paclitaxel, etoposide, etoposide phosphate, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomycin C, methotrexate, dichloromethotrexate, edatrexate, tiazofurin, ribavirin, EICAR, deferoxamine, ratitrexed, tegafur-uracil, cytosine arabinoside, fludarabine, EB 1089, CB 1093, KH 1060, lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, actinomycin D, bleomycin A2, bleomycin B2, peplomycin, pegylated liposomal doxorubicin, pirarubicin, zorubicin, verapamil, thapsigargin, thalidomide, lenalidomide, axitinib (AG013736), bosutinib (SKI-606), cediranib (AZD2171), dasatinib (BMS-354825), erlotinib, gefitinib, lapatinib, lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib, semaxanib (semaxinib, SU5416), sunitinib (SU11248), toceranib, vandetanib (ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab, bevacizumab, rituximab, cetuximab, panitumumab, ranibizumab, sorafenib, everolimus, alemtuzumab, gemtuzumab, ozogamicin, temsirolimus, ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992, SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120, AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, XL228, rapamycin, temsirolimus (CCI-779), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe), OSI-027 (OSI), oblimersen, leucovorin, pemetrexed, cyclophosphamide, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, methopterin, porfiromycin, melphalan, leurosidine, leurosine, trabectedin, discodermolide, and hexamethylmelamine, or a pharmaceutically acceptable salt thereof.

27. The use of claim 25, wherein the second therapeutic agent is selected from

(i) an agent that inhibits IgE production or activity,

(ii) an anti-inflammatory drug,

(iii) anticoagulants,

(iv) a biotherapeutic agent,

(v) an anti-angiogenesis agents,

(vi) a diuretic agent,

(vii) a hormone or therapeutic peptide or protein, and

(viii) radiation therapy; optionally

wherein

(i) the agent that inhibits IgE production or activity is selected from TEI-9874, 2-(4-(6-cyclohexyloxy-2-naphtyloxy)phenylacetamide)benzoic acid, rapamycin, rapamycin analogs, TORC1 inhibitors, TORC2 inhibitors, anti-IgE antibodies, omalizumab, and TNX-901;

(ii) the anti-inflammatory drug is selected from acetylsalicylic acid, ibuprofen, naproxen, indomethacin, nabumetone, tolmetin, a corticosteroid, prednisone, chloroquine, and hydroxychloroquine;

(iii) the anticoagulant is selected from aspirin™, heparin, and coumadin;

(iv) the biotherapeutic agent is selected from tumor necrosis factor, interferon α, interferon γ, IL-1, IL-2, IL-4, IL-6, IL-12, GM-CSF, Herceptin™ (trastuzumab), T-DM1, bevacizumab, cetuximab, panitumumab, rituximab, and tositumomab;

(v) the anti-angiogenic agent is selected from metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutalin, isoetharine, tulobuterol, orciprenaline or (-)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]-amino]methyl]benzenemethanol;

(vi) the diuretic agent is selected from amiloride, anticholinergics, ipratropium, atropine and oxitropium;

(vii) the hormone or therapeutic peptide or protein is selected from cortisone, hydrocortisone, prednisolone, xanthines, aminophylline, choline theophyllinate, lysine theophyllinate, theophylline, insulin and glucagon; or
(viii) the radiation therapy is selected from external-beam therapy, internal radiation therapy, implant radiation, stereotactic radiosurgery, systemic radiation therapy, radiotherapy and permanent or temporary interstitial brachytherapy.

28. The use of claim 25, wherein the second therapeutic agent is a therapeutic antibody.

29. The use of claim 28, wherein the therapeutic antibody is anti-CD20 antibody.

30. The use of claim 28, wherein the therapeutic antibody is selected from cetuximab, panitumumab, trastuzumab, rituximab, tositumomab, alemtuzumab, bevacizumab, and gemtuzumab.

31. Use of a compound of claim 9 or claim 10, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of claim 9 or claim 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder in a subject, wherein the disorder is selected from one or more of cancer, bone disorder, inflammatory disease, immune disease, respiratory disease, thrombosis, and cardiac disease.

32. Use of a compound of claim 9 or 10, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of claim 9 or 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject.

33. The use of claim 32, wherein the cancer is a leukemia or a lymphoma.

34. The use of claim 32, wherein the cancer is selected from thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian,

prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS-related cancer, Kaposi's Sarcoma, mastocytosis, and viral-induced cancer.

35. The use of claim 32, wherein the cancer is selected from acute myelogenous leukemia (AML), acute lymphocytic leukemia, T-cell acute lymphocytic leukemia, chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia (CML), multiple myeloma (MM), myelodysplastic syndrome (MDS), human lymphotropic virus-type 1 (HTLV-1) leukemia, and B-cell acute lymphoblastic leukemia.

36. The use of claim 32, wherein the cancer is selected from diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, adult T-cell lymphoma, mantle cell lymphoma (MCL), Hodgkin disease, non-Hodgkin lymphomas, AIDS-related lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, multiple myeloma, and follicular lymphoma.

37. The use of claim 33, wherein the leukemia is chronic lymphocytic leukemia.

38. The use of claim 33, wherein the lymphoma is non-Hodgkin lymphoma.

39. The use of claim 33, wherein the lymphoma is diffuse large B-cell lymphoma.

40. The use of claim 33, wherein the lymphoma is mantle cell lymphoma.

41. The use of claim 33, wherein the lymphoma is adult T-cell lymphoma.

42 The use of any one of claims 31-41, further comprises use of one or more second therapeutic agents.

43. The use of claim 42, wherein the second therapeutic agent is a chemotherapeutic agent; optionally
wherein the chemotherapeutic agent is selected from mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes,

topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, anti-androgens, alkyl sulfonates, aziridines, ethylenimines, methylamelamines, nitrogen mustards, nitrosureas, folic acid analogues, purine analogues, folic acid replenishers, taxanes, anti-estrogens, LHRH agonists, photodynamic therapies, triazenes, platinum containing compounds, vinca alkaloids, taxoids, epipodophyllins, DHFR inhibitors, IMP dehydrogenase inhibitors, ribonucleotide reductase inhibitors, uracil analogues, cytocine analogues, Vitamin D analogues, isoprenylation inhibitors, dopaminergic neurotoxins, MDR inhibitors, Ca2+ ATPase inhibitors, tyrosine kinase inhibitors, proteasome inhibitors, and mTOR inhibitors; optionally wherein the chemotherapeutic agent is selected from the group consisting of imatinib, bortezomib, bicalutamide, adriamycin, thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide, trimethylolomelamine, chlorambucil, chlornaphazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, chlorozotocin, fotemustine, nimustine, ranimustine; aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, 5-fluorouracil (5-FU), denopterin, pteropterin, trimetrexate, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elfomithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguazone, mopidamol, nitracrine, pentostatin, phenamet; pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, sizofiran, spirogermanium; tenuazonic acid, triaziquone, 2,2',2"-trichlorotriethylamine, urethane,

vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside ("Ara-C"), paclitaxel, docetaxel, retinoic acid, esperamicins, capecitabine, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, toremifene, flutamide, nilutamide, leuprolide, goserelin, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, mitomycin C, mitoxantrone, vincristine, vinorelbine, navelbine, novantrone, teniposide, daunomycin, aminopterin, xeloda, ibandronate, camptothecin-11 (CPT-11), topoisomerase inhibitor RFS 2000, difluoromethylornithine (DMFO), tamoxifen, raloxifene, megestrol, vertoporfin(BPD-MA), phthalocyanine, photosensitizer Pc4, demethoxy-hypocrellin A (2BA-2-DMHA), carmustine (BCNU), lomustine (CCNU), treosulfan, temozolomide, oxaliplatin, DHA-paclitaxel, Taxoprexin, PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX, ANG1005, paclitaxel-EC-1, glucose-conjugated paclitaxel, etoposide, etoposide phosphate, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomycin C, methotrexate, dichloromethotrexate, edatrexate, tiazofurin, ribavirin, EICAR, deferoxamine, ratitrexed, tegafur-uracil, cytosine arabinoside, fludarabine, EB 1089, CB 1093, KH 1060, lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, actinomycin D, bleomycin A2, bleomycin B2, peplomycin, pegylated liposomal doxorubicin, pirarubicin, zorubicin, verapamil, thapsigargin, thalidomide, lenalidomide, axitinib (AG013736), bosutinib (SKI-606), cediranib (AZD2171), dasatinib (BMS-354825), erlotinib, gefitinib, lapatinib, lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib, semaxanib (semaxinib, SU5416), sunitinib (SU11248), toceranib, vandetanib (ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab, bevacizumab, rituximab, cetuximab, panitumumab, ranibizumab, sorafenib, everolimus, alemtuzumab, gemtuzumab, ozogamicin, temsirolimus, ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992, SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120, AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, XL228, rapamycin, temsirolimus (CCI-779), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe), OSI-027 (OSI), oblimersen,

leucovorin, pemetrexed, cyclophosphamide, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, methopterin, porfiromycin, melphalan, leurosidine, leurosine, trabectedin, discodermolide, and hexamethylmelamine, or a pharmaceutically acceptable salt thereof.

44. The use of claim 42 wherein the second therapeutic agent is selected from
(i) an agent that inhibits IgE production or activity,
(ii) an anti-inflammatory drug,
(iii) anticoagulants,
(iv) a biotherapeutic agent,
(v) an anti-angiogenesis agents,
(vi) a diuretic agent,
(vii) a hormone or therapeutic peptide or protein, and
(viii) radiation therapy; optionally
wherein
(i) the agent that inhibits IgE production or activity is selected from TEI-9874, 2-(4-(6-cyclohexyloxy-2-naphtyloxy)phenylacetamide)benzoic acid, rapamycin, rapamycin analogs, TORC1 inhibitors, TORC2 inhibitors, anti-IgE antibodies, omalizumab, and TNX-901;
(ii) the anti-inflammatory drug is selected from acetylsalicylic acid, ibuprofen, naproxen, indomethacin, nabumetone, tolmetin, a corticosteroid, prednisone, chloroquine, and hydroxychloroquine;
(iii) the anticoagulant is selected from aspirin™, heparin, and coumadin;
(iv) the biotherapeutic agent is selected from tumor necrosis factor, interferon α, interferon γ, IL-1, IL-2, IL-4, IL-6, IL-12, GM-CSF, Herceptin™ (trastuzumab), T-DM1, bevacizumab, cetuximab, panitumumab, rituximab, and tositumomab;
(v) the anti-angiogenic agent is selected from metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutalin,

isoetharine, tulobuterol, orciprenaline or (-)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]-amino]methyl]benzenemethanol;
(vi) the diuretic agent is selected from amiloride, anticholinergics, ipratropium, atropine and oxitropium;
(vii) the hormone or therapeutic peptide or protein is selected from cortisone, hydrocortisone, prednisolone, xanthines, aminophylline, choline theophyllinate, lysine theophyllinate, theophylline, insulin and glucagon; or
(viii) the radiation therapy is selected from external-beam therapy, internal radiation therapy, implant radiation, stereotactic radiosurgery, systemic radiation therapy, radiotherapy and permanent or temporary interstitial brachytherapy.

45. The use of claim 42, wherein the second therapeutic agent is a therapeutic antibody.

46. The use of claim 45, wherein the therapeutic antibody is anti-CD20 antibody.

47. The use of claim 45, wherein the therapeutic antibody is selected from cetuximab, panitumumab, trastuzumab, rituximab, tositumomab, alemtuzumab, bevacizumab, and gemtuzumab.

48. The use of claim 47, wherein the therapeutic antibody is rituximab.

49. The use of claim 43, wherein the chemotherapeutic agent is nitrogen mustard.

50. The use of claim 43, wherein the chemotherapeutic agent is chlorambucil.


51. The use of claim 31, wherein the disorder is an inflammatory disease or immune disease.

52 The use of claim 51, wherein the inflammatory disease or immune disease is rheumatoid arthritis.

53 The use of claim 31, wherein the disorder is a respiratory disease.


54. The use of claim 53, wherein the respiratory disease is asthma.

55. A compound of the formula:



(Compound 292).


56. A process for preparing a compound of formula:



or a pharmaceutically acceptable salt thereof, wherein

R^3 is halo;


comprising deprotecting a compound of formula:




wherein the deprotection occurs in the presence of an acid.

57. The process of claim 56, wherein the acid is HCl.


58. The process of claim 56 or claim 57, wherein the compound of formula:



is prepared by a process comprising reacting a compound of formula:




with a compound of formula:




59. The process of claim 58, wherein the reaction occurs in the presence of N,N-diisopropylethylamine and n-butanol.

60. The process of claim 58 or claim 59, wherein the compound of formula:




is prepared by a process comprising an intramolecular ring closure of a compound of formula:




.

61. The process of claim 60, wherein the intramolecular ring closure occurs in the presence of hydrochloric acid and methanol.


62. The process of claim 60 or claim 61, wherein the compound of formula:



is prepared by a process comprising reacting a compound of formula:




with a compound of formula:




63. The process of claim 62, wherein the reaction occurs in the presence of hexamethylphosphoramide and n-butyllithium.

64. The process of claim 62 or claim 63, wherein the compound of formula:




is prepared by a process comprising reacting a compound of formula:




with N,O-dimethylhydroxylamine hydrochloride.

65. The process of claim 64, wherein the reaction occurs in the presence of triethylamine, hydroxybenzotriazole, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.


66. The process of claim 60 or claim 61, wherein the compound of formula:



is prepared by a process comprising reacting a compound of formula:




with a compound of formula:




67. The process of claim 66, wherein the reaction occurs in the presence of hexamethylphosphoramide and n-butyllithium.

68. The process of claim 66 or claim 67, wherein the compound of formula:




is prepared by a process comprising reacting a compound of formula:




with di-tert-butyl dicarbonate.

69. The process of claim 68, wherein the reaction occurs in the presence of $NaHCO_3$.

70. The process of claim 68 or claim 69, wherein the compound of formula:



is prepared by a process comprising reacting a compound of formula:



with methanol.

71. The process of claim 70, wherein the reaction occurs in the presence of thionyl chloride.

72. The process of any one of claims 56–71, wherein R^3 is Cl.

73. A compound of any one of claims 1-11 or a pharmaceutical composition of claim 12 or 13, for use in the treatment of a disorder in a subject, wherein said disorder is one or more of cancer, bone disorder, inflammatory disease, immune disease, respiratory disease, thrombosis, or cardiac disease; or for use in the treatment of asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder (COPD), psoriasis, multiple sclerosis, disorders related to diabetic complications, lupus erythematosus, scleroderma, graft versus host disease, restenosis, or atherosclerosis.